IntoCell Company Description

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer.

It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers.

In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs.

The company was founded in 2015 and is based in Daejeon, South Korea.

IntoCell, Inc.

Country	South Korea
Founded	2015
Industry	Biological Products, Except Diagnostic Substances
CEO	Tae-Kyo Park

Contact Details

Address: 101, Sinildong-ro Daejeon South Korea
Phone	82 4 2716 0083
Website	intocell.com

Stock Details

Ticker Symbol	287840
Exchange	KOSDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Tae-Kyo Park	Chief Executive Officer
Young-Suk Suh	Chief Financial Officer